Nuclear medicine techniques for the study of breast cancer

[1]  A. Chiti,et al.  Radiopharmaceuticals for Breast Cancer Imaging , 1997, Tumori.

[2]  M. Cremonesi,et al.  Optimization of Axillary Lymphoscintigraphy to Detect the Sentinel Node in Breast Cancer , 1997, Tumori.

[3]  M. Greco,et al.  Breast cancer staging using technetium-99m sestamibi and indium-111 pentetreotide single-photon emission tomography , 1997, European Journal of Nuclear Medicine.

[4]  R. Hustinx,et al.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose , 1996, European Journal of Nuclear Medicine.

[5]  P. F. Winter,et al.  Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry , 1996, European Journal of Nuclear Medicine.

[6]  L. Mansi,et al.  Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases , 1996, European Journal of Nuclear Medicine.

[7]  H. Biersack,et al.  Scintimammography with technetium-99m methoxyisobutylisonitrile: comparison with mammography and magnetic resonance imaging , 1996, European Journal of Nuclear Medicine.

[8]  W. Yang,et al.  Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography , 1996, European Journal of Nuclear Medicine.

[9]  M. Greco,et al.  Prone scintimammography in patients with non-palpable breast lesions. , 1996, Anticancer research.

[10]  M. Greco,et al.  Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer. , 1996, International journal of oncology.

[11]  E. Endert,et al.  The stereoisomers of 17α-[123I]iodovinyloestradiol and its 11α-methoxy derivative evaluated for their oestrogen receptor binding in human MCF-7 cells and rat uterus, and their distribution in immature rats , 1996, European Journal of Nuclear Medicine.

[12]  Terry Jones,et al.  The role of positron emission tomography within the spectrum of medical imaging , 1996, European Journal of Nuclear Medicine.

[13]  R L Wahl,et al.  Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  E. Pauwels,et al.  Applications of 99mTC-Sestamibi in Oncology , 1996, Tumori.

[15]  A. Luxen,et al.  PET radiopharmaceuticals in Europe: Current use and data relevant for the formulation of summaries of product characteristics (SPCs) , 1995, European Journal of Nuclear Medicine.

[16]  J E Mortimer,et al.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  A. Robidoux,et al.  Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  J. Thompson,et al.  Mammary lymphoscintigraphy in breast cancer. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  I. Mena,et al.  Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  N. Alazraki,et al.  Lymphoscintigraphy and the intraoperative gamma probe. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  A. Giuliano,et al.  Improved Axillary Staging of Breast Cancer with Sentinel Lymphadenectomy , 1995, Annals of surgery.

[22]  L. Mansi,et al.  Breast Cancer Detection With Tc-99m Tetrofosmin , 1995, Clinical nuclear medicine.

[23]  I. Mena,et al.  Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. , 1995, Radiology.

[24]  R. Pickett,et al.  Mechanism of uptake of technetium-tetrofosmin. I: Uptake into isolated adult rat ventricular myocytes and subcellular localization , 1995, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[25]  J. Maublant,et al.  Mechanism of uptake of technetium-tetrofosmin. II: Uptake into isolated adult rat heart mitochondria , 1995, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[26]  A. Bischof Delaloye,et al.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion? , 1995, European Journal of Nuclear Medicine.

[27]  F. Smith,et al.  Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  J. Bergh,et al.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Salvatore,et al.  Technetium-99m-methylene diphosphonate scintimammography to image primary breast cancer. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  U. Veronesi,et al.  Preliminary-results of preoperative axillary radioimmunoscintigraphy with in-111 b72.3 in breast-cancer. , 1995, International journal of oncology.

[31]  Q. Sun,et al.  99Tcm-MIBI mammoscintigraphy of breast masses: early and delayed imaging. , 1995, Nuclear medicine communications.

[32]  J. Moretti,et al.  Can nuclear medicine predict response to chemotherapy? , 1995, European Journal of Nuclear Medicine.

[33]  A. Chiti,et al.  Case Report: Technetium-99M-Hexakis-2-Methoxy-Isobutyl-Isonitrile Imaging of Breast Cancer and Myocardial Infarction in the Same Patient , 1994, Tumori.

[34]  M. Cuesta,et al.  Gamma probe‐guided sentinel node biopsy to select patients with melanoma for lymphadenectomy , 1994, The British journal of surgery.

[35]  K. Go,et al.  Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. , 1994, Nuclear medicine and biology.

[36]  R. Danieli,et al.  Technetium-99m sestamibi: an indicator of breast cancer invasiveness , 1994, European Journal of Nuclear Medicine.

[37]  Z. Burak,et al.  Evaluation of palpable breast masses with 99Tcm‐MIBI: a comparative study with mammography and ultrasonography , 1994, Nuclear medicine communications.

[38]  Shuu-Jiun Wang,et al.  The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses , 1994, European Journal of Nuclear Medicine.

[39]  R. Wahl,et al.  Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  I. Mena,et al.  Prone scintimammography in patients with suspicion of carcinoma of the breast. , 1994, Journal of the American College of Surgeons.

[41]  I. Mena,et al.  Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi , 1994, European Journal of Nuclear Medicine.

[42]  J. Jeekel,et al.  Somatostatin-receptor scintigraphy in primary breast cancer , 1994, The Lancet.

[43]  Lee P. Adler,et al.  Positron emission tomography and breast masses: Comparison with clinical, mammographic, and pathological findings , 1994, Annals of Surgical Oncology.

[44]  B. Cady,et al.  The need to reexamine axillary lymph node dissection in invasive breast cancer , 1994, Cancer.

[45]  M. Kavanah,et al.  A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  H. Gallion,et al.  Images of estrogen-receptor-positive breast tumors produced by estradiol labeled with iodine I 123 at 16 alpha. , 1993, Archives of surgery.

[47]  D. Weaver,et al.  Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. , 1993, Surgical oncology.

[48]  W H Wong,et al.  Positron Emission Tomography of Glucose Metabolism in Breast Cancer , 1993, Annals of the New York Academy of Sciences.

[49]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Welch,et al.  16β-((18F)Fluoro)estrogens: Systematic Investigation of a New Series of Fluorine-18-Labeled Estrogens as Potential Imaging Agents for Estrogen-Receptor-Positive Breast Tumors. , 1993 .

[51]  K. Någren,et al.  Expert Testimony versus Junk Science , 1993, Environmental Health Perspectives.

[52]  Michael E. Phelps,et al.  Cancer Detection with Whole‐Body PET Using 2‐[18F]Fluoro‐2-Deoxy‐D-Glucose , 1993, Journal of computer assisted tomography.

[53]  G. Hortobagyi,et al.  Positron emission tomography with fluorine‐18‐deoxyglucose in the detection and staging of breast cancer , 1993, Cancer.

[54]  J L Sunshine,et al.  Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.

[55]  M. Welch,et al.  16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors. , 1993, Journal of medicinal chemistry.

[56]  M. Welch,et al.  Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. , 1993, Journal of medicinal chemistry.

[57]  K. Någren,et al.  Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. , 1993, British Journal of Cancer.

[58]  M. Baum,et al.  Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen. , 1993, British Journal of Cancer.

[59]  R. Ott,et al.  c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  A. Cochran,et al.  Management of Early-Stage Melanoma by Intraoperative Lymphatic Mapping and Selective Lymphadenectomy: An Alternative to Routine Elective Lymphadenectomy or “Watch and Wait” , 1992 .

[61]  M E Phelps,et al.  The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. , 1992, Annals of surgery.

[62]  M. Welch,et al.  Erratum: Preparation and evaluation of 17-ethynyl-substituted 16α-[18F]fluoroestradiols: selective receptor-based PET imaging agents (Nuclear Medicine and Biology - International Journal of Radiation Applications and instrumentation Part B (Vol.nr. 19) (363-374)) , 1992 .

[63]  S M Larson,et al.  Radioimmunodetection in cancer identification. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  M. Welch,et al.  Preparation and evaluation of 17-ethynyl-substituted 16 alpha-[18F]fluoroestradiols: selective receptor-based PET imaging agents. , 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[65]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[66]  M. Kır,et al.  Clinical Experience with Tc‐99m MIBI Imaging in Patients with Malignant Tumors Preliminary Results and Comparison with TI‐201 , 1992, Clinical nuclear medicine.

[67]  M. Mintun,et al.  Positron Tomographic Assessment of 16α-[18F] Fluoro-17β-Estradiol Uptake in Metastatic Breast Carcinoma , 1991 .

[68]  M J Welch,et al.  Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[69]  G. Hortobagyi,et al.  Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[70]  S. Müller,et al.  [Tumor scintigraphy using 123I-labeled estradiol in breast cancer--receptor scintigraphy]. , 1991, Nuklearmedizin. Nuclear medicine.

[71]  R L Wahl,et al.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.

[72]  A. Rosenberg,et al.  CT-pathologic correlation of axillary lymph nodes in breast carcinoma. , 1991, Journal of computer assisted tomography.

[73]  O. Eber,et al.  The immunoscintigraphic use of Tc‐99m‐labelled monoclonal anti‐CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer , 1991, International journal of cancer.

[74]  T Jones,et al.  Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer , 1991, International journal of cancer.

[75]  R. Wahl,et al.  Positron-emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose. , 1991, The New England journal of medicine.

[76]  L L Fajardo,et al.  Mammography-guided stereotactic fine-needle aspiration cytology of nonpalpable breast lesions: prospective comparison with surgical biopsy results. , 1990, AJR. American journal of roentgenology.

[77]  M. Kaminski,et al.  The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[78]  D. Hayes.  Axillary lymphoscintigraphy for breast cancer: should we do it? Can we do it? , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[79]  K. Boo-Chai,et al.  Mammographic screening and mortality from breast cancer: The Malmo mammographic screening trial , 1990 .

[80]  J. Mckillop,et al.  201Tl scintigraphy in the staging of lung cancer, breast cancer and lymphorna , 1990, Nuclear medicine communications.

[81]  P. Major,et al.  Breast tumor radioimmunodetection with a 111In-labeled monoclonal antibody (MA5) against a mucin-like antigen. , 1990, Cancer research.

[82]  M. Ito,et al.  Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography. , 1989, Journal of computer assisted tomography.

[83]  Y. M. Chen,et al.  Esophageal motility: assessment with synchronous video tape fluoroscopy and manometry. , 1989, Radiology.

[84]  S. Ciatto,et al.  Nonpalpable breast lesions: stereotaxic fine-needle aspiration cytology. , 1989, Radiology.

[85]  R. J. Brenner,et al.  THALLIUM SCINTIGRAPHY IN PRIMARY CARCINOMA OF THE BREAST: EVALUATION OF PRIMARY AND AXILLARY METASTASIS , 1989 .

[86]  H. Yamamoto,et al.  New simplified lymphoscintigraphic technique in patients with breast cancer. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[87]  J. Taylor‐Papadimitriou,et al.  Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancer. , 1989, British Journal of Cancer.

[88]  J. Tjandra,et al.  Immunolymphoscintigraphy for the detection of lymph node metastases from breast cancer. , 1989, Cancer research.

[89]  M. Mintun,et al.  Breast cancer: PET imaging of estrogen receptors. , 1988, Radiology.

[90]  M. Ercan,et al.  Parasternal lymphoscintigraphy using 99Tcm‐dextran , 1988, Nuclear medicine communications.

[91]  J. Weinstein,et al.  Targeting of murine radiolabeled monoclonal antibodies in the lymphatics. , 1987, Cancer research.

[92]  E. Kubista,et al.  Immunolymphscintigraphy of axillary lymph node metastases in breast cancer patients using monoclonal antibodies: first clinical findings. , 1986, Anticancer research.

[93]  B. Engelstad,et al.  Phase 1 immunolymphoscintigraphy with an In-111-labeled antimelanoma monoclonal antibody. , 1986, Radiology.

[94]  A. D. den Outer,et al.  Breast scintigraphy with 99Tc‐diethylene triamine penta‐acetic acid for the detection of malignant disease , 1986, The British journal of surgery.

[95]  R. Mclean,et al.  Prognostic value of axillary lymphoscintigraphy in breast carcinoma patients. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[96]  M. Salvatore,et al.  Pre‐operative axillary lymphoscintigraphy in breast cancer: experience with sub‐areolar injection of 99Tcm-nanocolloidal albumin , 1986, Nuclear medicine communications.

[97]  J. Andrews,et al.  IMMUNOSCINTIGRAPHY FOR DETECTION OF LYMPH NODE METASTASES FROM BREAST CANCER , 1984, The Lancet.

[98]  M. Welch,et al.  Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. , 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[99]  Terry Jones,et al.  POSITRON EMISSION TOMOGRAPHY FOR IN-VIVO MEASUREMENT OF REGIONAL BLOOD FLOW, OXYGEN UTILISATION, AND BLOOD VOLUME IN PATIENTS WITH BREAST CARCINOMA , 1984, The Lancet.

[100]  Mahoney Lj,et al.  Predicting nodal metastases in breast cancer by lymphoscintigraphy. , 1983 .

[101]  K. Hisada,et al.  Clinical Experience of Tumor Imaging with 201TI-Chloride , 1977 .

[102]  G. Johnston,et al.  Breast scintigraphy with /sup 99m/Tc-pertechnetate and $sup 67$Ga-citrate , 1975 .

[103]  G. Johnston,et al.  Breast scintigraphy with 99mTc-pertechnetate and 67Ga-citrate. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  A. Serafini,et al.  Radionuclide breast scanning in carcinoma of the breast. , 1974, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[105]  F. Bonte,et al.  Experimental pertechnetate mammography. , 1974, Radiology.

[106]  H. Minn,et al.  [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer , 2004, European Journal of Nuclear Medicine.

[107]  S. Allan.  The prospects for imaging lymph nodes in breast cancer , 2004, European Journal of Nuclear Medicine.

[108]  Andrew D. A. Maidment,et al.  Digital Mammography , 2019, Advances in Clinical Radiology.

[109]  R. Schulz-Wendtland,et al.  Fine-Needle Aspiration and Core Biopsy , 2000 .

[110]  A. Tulusan.  Mammographic-Pathological Correlations , 2000 .

[111]  J. Teubner.  Echomammography: Technique and Results , 2000 .

[112]  I. Schreer,et al.  Breast Cancer Screening Projects: Results , 2000 .

[113]  E. Sickles,et al.  Radiological Diagnosis of Breast Diseases , 2000, Medical Radiology.

[114]  M. Greco,et al.  Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[115]  G. Tienhoven,et al.  PP-4-19 Imaging of tumours in breast cancer patients with the estrogen receptor specific radioligand Z-[I-123]MIVE , 1996 .

[116]  R. Wahl,et al.  New methods for imaging the breast: techniques, findings, and potential. , 1995, AJR. American journal of roentgenology.

[117]  J. Ortman-Nabi,et al.  Diagnosis of breast carcinoma with radiolabeled monoclonal antibodies (MoAbs) to carcinoembryonic antigen (CEA) and human milk fat globulin (HMFG). , 1995, Cancer investigation.

[118]  David J. Yang,et al.  Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. , 1994, Life sciences.

[119]  M. Petrén-mallmin.  Clinical and experimental imaging of breast cancer metastases in the spine. , 1994, Acta radiologica. Supplementum.

[120]  A D Waxman,et al.  Thallium scintigraphy in the evaluation of mass abnormalities of the breast. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[121]  M. Welch,et al.  Synthesis, radiolabeling and tissue distribution of 11 beta-fluoroalkyl- and 11 beta-fluoroalkoxy-substituted estrogens: target tissue uptake selectivity and defluorination of a homologous series of fluorine-18-labeled estrogens. , 1993, Nuclear medicine and biology.

[122]  M. Welch,et al.  16β-[18F]fluoromoxestrol : a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors , 1993 .

[123]  R. Hawkins,et al.  Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. , 1993, International journal of radiation oncology, biology, physics.

[124]  J. Katzenellenbogen.  The pharmacology of steroid radiopharmaceuticals: specific and non-specific binding and uptake selectivity , 1992 .

[125]  G. Masarotto,et al.  Significance of internal mammary lymphoscintigraphy (IML) in clinical staging and prognosis of breast cancer , 1992 .

[126]  P. Bräutigam,et al.  Tumor-Szintigraphie mit 123J-markiertem Östradiol beim Mammakarzinom - Rezeptorszintigraphie , 1991, Nuklearmedizin.

[127]  M. Welch,et al.  Target tissue uptake selectivity of three fluorine-substituted progestins: potential imaging agents for receptor-positive breast tumors. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[128]  S. Heywang-Köbrunner.  Clinical application of contrast-enhanced MRI , 1990 .

[129]  J. Taylor‐Papadimitriou,et al.  Immunoscintigraphy with 131I‐labelled HMFG2 and HMFG2 F(ab')2 in the pre‐operative detection of clinical and subclinical lymph node metastases in breast cancer patients , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[130]  E. Kuschnir,et al.  Lymphscintigraphies of the internal mammary ganglion chain: our experience. , 1986, European journal of gynaecological oncology.

[131]  D. Goldenberg,et al.  Diagnosis and treatment of neoplasms with radionuclide-labeled antibodies. , 1985, Seminars in nuclear medicine.

[132]  G. Ege.  Lymphoscintigraphy--techniques and applications in the management of breast carcinoma. , 1983, Seminars in nuclear medicine.